Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether low pressure changes serious adverse events compared with standard pressure pneumoperitoneum (very low certainty).
1 finding from 1 review
Serious adverse events · primary hepatocellular carcinoma
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐serious adverse events: leukopenia · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: leukopenia compared with TACE (very low certainty).
1 finding from 1 review
Serious adverse events · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).
1 finding from 1 review
Other serious adverse events · adult patients with hypertension
Lower BP target may leads to higher other serious adverse events compared with standard BP target (low certainty).
1 finding from 1 review
RR 1.44 [1.32, 1.59]
Studies not reported
Low
Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).
1 finding from 1 review
Serious adverse events ( · children with either displaced distal radius fracture with intact or displaced ulna fracture (both‐bone fracture), or minimally displaced…
1 finding from 1 review
Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).
1 finding from 1 review
Total serious adverse events · cardiovascular disease with high blood pressure
Lower blood pressure targets showed no clear difference in total serious adverse events compared with standard blood pressure targets (low certainty).
1 finding from 1 review
Total serious adverse events№ of participants: 18165(6 RCTs) · adult patients with hypertension
Lower BP target showed no clear difference in total serious adverse events№ of participants: 18165(6 RCTs) compared with standard BP target (moderate certainty).
1 finding from 1 review
RR 1.04 [0.99, 1.08]
Studies not reported
Moderate
Serious adverse eventsd · adults with low back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Proportion of participants with ≥ 1 serious adverse events · people with acute subarachnoid haemorrhage
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events or complications of treatment
1 finding from 1 review